Trump’s FDA Layoffs Trigger Chaos: Drug Approvals at Risk
Sweeping Cuts Threaten Public Health and Innovation The Trump administration’s drastic layoffs at the U.S. Food and Drug Administration (FDA) have ignited widespread alarm among public health experts, industry leaders, and former agency officials. These sweeping personnel cuts, affecting approximately 3,500 employees, are part of a broader effort led by Health and Human Services Secretary Robert F. Kennedy Jr. to slash the federal workforce. However, the consequences of this aggressive restructuring are already reverberating through the FDA, jeopardizing its ability to review and approve new drugs, oversee medical device safety, and ensure the efficacy of vaccines. As key scientists, administrative staff, and division leaders are dismissed, concerns are mounting over potential delays in life-saving treatments reaching patients and the erosion of decades of regulatory progress. This mass termination initiative, which began with notices sent out earlier this week, has targeted crit...